Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40QK8 | ISIN: US05330T2050 | Ticker-Symbol:
NASDAQ
06.06.25 | 21:36
1,380 US-Dollar
0,00 % 0,000
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
AUTONOMIX MEDICAL INC Chart 1 Jahr
5-Tage-Chart
AUTONOMIX MEDICAL INC 5-Tage-Chart

Aktuelle News zur AUTONOMIX MEDICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
AUTONOMIX MEDICAL Aktie jetzt für 0€ handeln
DoAutonomix set to expand cancer pain treatment trial2
DoAutonomix erweitert klinische Studie zur Behandlung von Krebsschmerzen-
DoAutonomix Medical, Inc. Granted Approval to Expand Proof-of-Concept Human Clinical Study, Doubling Potential Addressable Market Beyond Pancreatic Cancer Pain4
29.05.Autonomix Medical, Inc. - 10-K, Annual Report2
22.05.AMIX Stock May Climb Following Key U.S. Patent for Nerve-Sensing Tech2
16.05.Autonomix picks up key nerve ablation catheter patent1
14.05.Autonomix Medical, Inc.: Autonomix CEO Brad Hauser to Present at Virtual Investor's Closing Bell Event1
13.05.Autonomix plans expansion phase for cancer pain trial2
13.05.Brad Hauser, CEO of Autonomix Medical, Inc. Outlines Follow-On Expansion Study Expected to Begin in Q2 2025, Potentially Doubling Addressable Market183Discussion in Virtual Investor CEO Connect focuses on Company's planned follow-on market expansion study phase ("PoC 2") of proof-of-concept trial; Access Here Additional indications potentially double...
► Artikel lesen
05.05.Autonomix reports significant pain relief in cancer trial2
05.05.Autonomix Medical, Inc.: Autonomix Highlights Compelling Patient Testimonial Showing Rapid Pain Relief from First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain177Video testimonial demonstrates pain reduction after transvascular nerve ablation, suggesting potential for improving quality of life in late-stage cancer care Patient testimonial now available here...
► Artikel lesen
01.05.Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor "What This Means" Segment Highlighting Key Learnings from First-In-Human Trial and Extension into Visceral Cancer Pain1
30.04.Autonomix Medical Reports Positive Results In First Human Trial For Cancer Pain, Stock Down1
30.04.Autonomix erzielt Fortschritte bei Schmerzbehandlung in Krebsstudien2
30.04.Autonomix advances pain treatment in cancer trials1
30.04.Autonomix Medical, Inc. Reports Positive Outcomes in Initial Phase of First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain and Initiates Market Expansion Study for Visceral Cancer Pain92Initial trial phase ("PoC 1") achieved key learnings and met all study objectives Clinically meaningful pain reduction with 100% of responders achieving zero opioid use at 7 days post-procedure and...
► Artikel lesen
30.04.Autonomix Medical, Inc. - 8-K, Current Report-
24.04.Autonomix Medical, Inc. Technology and Early Proof-of-Concept Study Results to be Featured in Poster Presentation at the World-Leading Course in Interventional Cardiovascular Medicine, EuroPCR1
17.04.Autonomix Medical, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)101THE WOODLANDS, TX, April 17, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to...
► Artikel lesen
16.04.Autonomix Medical sichert sich neues europäisches Patent für Nerventechnologie1
Weiter >>
49 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1